## **Supplementary Information**

MRI-guided Biopsy in Active Surveillance of Prostate Cancer

Adam Kinnaird MD PhD<sup>1,2,\*</sup>, Nitin K. Yerram MD<sup>3\*</sup>, Luke O'Connor BS<sup>3</sup>, Wayne Brisbane MD<sup>1</sup>, Vidit Sharma MD MPH<sup>1</sup>, Ryan Chuang MD MSc<sup>1</sup>, Rajiv Jayadevan<sup>1</sup>, Michael Ahdoot MD<sup>3</sup>, Michael Daneshvar MD<sup>3</sup>, Alan Priester PhD<sup>4</sup>, Merdie Delfin MSN NP<sup>1</sup>, Elizabeth Tran BSc<sup>1</sup>, Danielle E. Barsa BSc<sup>1</sup>, Anthony Sisk MD<sup>5</sup>, Robert E. Reiter MD<sup>1</sup>, Ely Felker MD<sup>6</sup>, Steve Raman MD<sup>6</sup>, Lorna Kwan MPH<sup>1</sup>, Peter L. Choyke MD<sup>7</sup>, Maria J. Merino MD<sup>8</sup>, Bradford J. Wood MD<sup>9</sup>, Baris Turkbey MD<sup>7</sup>, Peter A. Pinto MD<sup>3</sup> and Leonard S. Marks MD<sup>1</sup>

\*Contributed equally to this work

## **Affiliations**

- <sup>1</sup>Department of Urology, David Geffen School of Medicine, UCLA
- <sup>2</sup>Divison of Urology, Department of Surgery, University of Alberta
- <sup>3</sup>Urologic Oncology Branch, National Cancer Institute, National Institutes of Health
- <sup>4</sup>Department of Bioengineering, UCLA
- <sup>5</sup>Department of Pathology & Laboratory Medicine, UCLA
- <sup>6</sup>Department of Radiological Sciences, UCLA
- <sup>7</sup>Molecular Imaging Program, National Cancer Institute, National Institutes of Health
- <sup>8</sup>Laboratory of Pathology, National Cancer Institute, National Institutes of Health
- <sup>9</sup>Center for Interventional Oncology, National Cancer Institute, National Institutes of Health

## **Supplementary Figure Legends:**

Supplementary Figure 1. Probability of upgrading-free survival to ≥GG2 during Active Surveillance of prostate cancer after an MRI-guided confirmatory biopsy.

(Upper panel) Overall probability of upgrading-free survival.

(Middle panel) Probability of upgrading-free survival stratified by cancer-containing core type at confirmatory biopsy (Black, negative systematic and negative targeted cores; Blue, positive systematic and negative targeted cores; Yellow, negative systematic and positive targeted cores; Green, positive systematic and positive targeted cores).

(Bottom panel) Probability of upgrading-free survival stratified by Gleason Grade Group at confirmatory biopsy (Blue, no cancer; Red, Grade Group 1).

Abbreviations: (GG, Grade Group; Sys, Systematic biopsy)